- Home
- JRS vs NKTX Comparison
JRS vs NKTX Comparison
Compare JRS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- NKTX
- Stock Information
- Founded
- JRS 2001
- NKTX 2015
- Country
- JRS United States
- NKTX United States
- Employees
- JRS N/A
- NKTX N/A
- Industry
- JRS Finance/Investors Services
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- NKTX Health Care
- Exchange
- JRS Nasdaq
- NKTX Nasdaq
- Market Cap
- JRS 267.5M
- NKTX 225.1M
- IPO Year
- JRS N/A
- NKTX 2020
- Fundamental
- Price
- JRS $8.31
- NKTX $2.34
- Analyst Decision
- JRS
- NKTX Strong Buy
- Analyst Count
- JRS 0
- NKTX 5
- Target Price
- JRS N/A
- NKTX $15.20
- AVG Volume (30 Days)
- JRS 86.6K
- NKTX 2.2M
- Earning Date
- JRS 01-01-0001
- NKTX 11-07-2024
- Dividend Yield
- JRS 8.87%
- NKTX N/A
- EPS Growth
- JRS N/A
- NKTX N/A
- EPS
- JRS N/A
- NKTX N/A
- Revenue
- JRS N/A
- NKTX N/A
- Revenue This Year
- JRS N/A
- NKTX N/A
- Revenue Next Year
- JRS N/A
- NKTX N/A
- P/E Ratio
- JRS N/A
- NKTX N/A
- Revenue Growth
- JRS N/A
- NKTX N/A
- 52 Week Low
- JRS $5.95
- NKTX $2.22
- 52 Week High
- JRS $8.00
- NKTX $16.24
- Technical
- Relative Strength Index (RSI)
- JRS 26.36
- NKTX 36.78
- Support Level
- JRS $9.44
- NKTX $2.22
- Resistance Level
- JRS $9.48
- NKTX $2.50
- Average True Range (ATR)
- JRS 0.13
- NKTX 0.23
- MACD
- JRS -0.10
- NKTX 0.01
- Stochastic Oscillator
- JRS 5.56
- NKTX 12.74
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.